Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Bupivacaine

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (1)
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Research Network

Common Treatments

  • Bupivacaine1
  • Bupivacaine With Epinephrine1
  • Normal Saline1
  • Water Spray Application1
  • Xylocain Cutaneous Spray Solution1

Active Sponsors

  • Ove Andersen1
  • Gaziantep Islam Science and Technology University1
  • Oracain II Aps1
  • University of North Carolina, Chapel Hill1

Top Investigators

Related Conditions

  • Medical Device Discomfort1

Activity Timeline